Evidence map›Paper›PMID 30569337›Full record

ArticleChemistry Central journal2018

Analysis of coumarin and angelica lactones in smokeless tobacco products.

Kevin McAdam, Trevor Enos, Carol Goss, Harriet Kimpton, Arif Faizi, Steve Edwards, Christopher Wright, Andrew Porter, Brad Rodu

Open access · goldAbstract read
In one paragraph

Article in Chemistry Central journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Kevin McAdamGroup Research & Development, British American Tobacco, Regents Park Road, Southampton, SO15 8TL, UK. Kevin@mcadamscience.com.
Trevor EnosGroup Research & Development, British American Tobacco, Regents Park Road, Southampton, SO15 8TL, UK.
Carol GossGroup Research & Development, British American Tobacco, Regents Park Road, Southampton, SO15 8TL, UK.
Harriet KimptonGroup Research & Development, British American Tobacco, Regents Park Road, Southampton, SO15 8TL, UK.
Arif FaiziGroup Research & Development, British American Tobacco, Regents Park Road, Southampton, SO15 8TL, UK.
Steve EdwardsGroup Research & Development, British American Tobacco, Regents Park Road, Southampton, SO15 8TL, UK.
Christopher WrightGroup Research & Development, British American Tobacco, Regents Park Road, Southampton, SO15 8TL, UK.
Andrew Porter, 3810 St. Antoine W, Montreal, QC, H4C 1B4, Canada.
Brad RoduDepartment of Medicine, School of Medicine, University of Louisville, Room 208, 505 South Hancock Street, Louisville, KY, 40202, USA.
British American Tobacco (United Kingdom) · GBUniversity of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differences in health risks between different styles of smokeless tobacco products (STPs) have prompted interest in their relative levels of toxic chemicals. We report here the development of methods for the analysis of STPs for coumarin and for α-angelica lactone (α-AL), both of which have been included in various published lists of tobacco toxicants. We have also determined the concentrations of these lactones in commercial STPs from the US and Sweden, representing 80-90% of the 2010 market share for all the major STP categories in these two countries: 65 products (plus two reference products) for coumarin and 66 commercial products for α-AL. For coumarin, methanol extracts of the STPs were analysed by HPLC/MS/MS. The lower limit of quantification (LOQ) and limit of detection (LOD) were, respectively, 100 and 30 ng coumarin/g of STP on a wet weight basis (WWB). Alpha-AL was determined via direct headspace GC/MS. The LOQ and LOD were 65 and 30 ng/g WWB respectively. Coumarin was detected In 3/33 Swedish snus, 5/13 US chewing tobaccos, 16/16 moist snuffs and 5/6 dry snuffs. Concentrations in those samples with quantifiable coumarin contents ranged from 186 to 1656 ng/g WWB. Concentrations of coumarin measured in this study were consistent with levels naturally found in tobacco. None of the STPs analysed would significantly contribute to coumarin exposure in consumers compared with dietary sources, and estimated exposure levels were 1000× lower than the European Food Safety Authority Tolerable Daily Intake. Hence the relevance of coumarin to the toxicity of STPs and its inclusion in the FDA's list of harmful and potentially harmful compounds list is questionable. Measurements of α-AL in these STPs found that the majority did not have quantifiable contents, however, for three STPs concentrations of α-AL were above the LOQ (116-140 ng/g WWB) and for four other STPs concentrations of α-AL could be estimated between the LOD and LOQ. Beta-angelica lactone was tentatively identified in three of the STPs but the levels could not be reliably quantified. The levels of α-AL in tobacco products are reported here for the first time, but the relevance of α-AL to the toxicity of STPs is also highly questionable given that it has GRAS status as a permitted food additive.

Indexed as

Angelica lactoneCoumarinSmokeless tobaccoSnuffSnus

Identifiers

PMID30569337
PMCPMC6768314
OpenAlexW2904082446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.